GPCR/G protein
All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
- B2237 Eletriptan HBrSummary: selective 5-HT1B and 5-HT1D receptor agonist
- B1682 BosentanSummary: Endothelin receptor antagonist
- B1521 Bosentan HydrateSummary: endothelin receptor antagonist
- B2229 Palonosetron HClSummary: 5-HT receptor antagonist
- B1754 Fenspiride HClSummary: α adrenergic and H1 histamine receptor antagonist
- B1204 Ondansetron hydrochloride dihydrateSummary: 5-HT3 receptor antagonist
- B1332 CarvedilolSummary: Potent β-adrenoceptor and α1-adrenoceptor antagonist
- B1477 Lurasidone HClTarget: 5-HT2 Receptors|D2 Receptors|5-HT1 Receptors|5-HT7 ReceptorsSummary: Dopamine D2/5-HT2A/5-HT7/5-HT1A inhibitor
- B2258 Tropisetron HydrochlorideTarget: 5-HT3 ReceptorsSummary: 5-HT3 receptor antagonist
- B1209 DoxazosinSummary: Quinazoline-derivative that selectively antagonizes postsynaptic α1-adrenergic receptors